Aspire Biopharma Holdings, Inc.
ASBP
$0.3366
-$0.0277-7.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 459.36% | 381.72% | 279.07% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 561.74% | 419.37% | 255.65% | -- | -- |
| Operating Income | -561.74% | -419.37% | -255.65% | -- | -- |
| Income Before Tax | -3,924.63% | -3,575.08% | -284.43% | -- | -- |
| Income Tax Expenses | 100.00% | 100.00% | 100.00% | -- | -- |
| Earnings from Continuing Operations | -3,920.57% | -3,571.33% | -284.16% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3,920.57% | -3,571.33% | -284.16% | -- | -- |
| EBIT | -561.74% | -419.37% | -255.65% | -- | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3,727.27% | -4,858.14% | -6,950.00% | -- | -- |
| Normalized Basic EPS | -589.33% | -530.19% | -8,600.00% | -- | -- |
| EPS Diluted | -3,727.27% | -4,858.14% | -6,950.00% | -- | -- |
| Normalized Diluted EPS | -589.33% | -530.19% | -8,600.00% | -- | -- |
| Average Basic Shares Outstanding | 94.81% | 101.62% | 111.86% | -- | -- |
| Average Diluted Shares Outstanding | 94.81% | 101.62% | 111.86% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |